Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMONASDAQ:DAWNNASDAQ:INVANASDAQ:IRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$6.53▼$12.51$799.18M1.391.37 million shs3.07 million shsDAWNDay One Biopharmaceuticals$6.31+0.2%$7.11$6.08▼$16.76$639.59M-1.241.11 million shs976,697 shsINVAInnoviva$19.12-0.2%$18.23$15.20▼$21.28$1.20B0.35641,422 shs836,010 shsIRONDisc Medicine$45.12-1.7%$45.33$30.82▼$68.73$1.56B0.77346,061 shs274,276 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+42.96%DAWNDay One Biopharmaceuticals+0.48%-4.26%-18.60%-36.01%-54.25%INVAInnoviva+0.95%+1.97%+4.99%+6.98%+21.36%IRONDisc Medicine-3.15%-8.39%+1.01%-15.97%+33.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDMOAvid Bioservices0.791 of 5 stars1.00.00.04.50.01.70.6DAWNDay One Biopharmaceuticals2.5883 of 5 stars4.60.00.00.03.02.50.0INVAInnoviva4.4497 of 5 stars3.51.00.04.23.72.51.9IRONDisc Medicine3.1196 of 5 stars4.51.00.00.03.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57384.49% UpsideINVAInnoviva 3.00Buy$55.00187.66% UpsideIRONDisc Medicine 3.09Buy$98.80118.97% UpsideCurrent Analyst Ratings BreakdownLatest CDMO, DAWN, IRON, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/5/2025DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$39.00 ➝ $34.003/3/2025IRONDisc MedicineScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$73.00 ➝ $75.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14DAWNDay One Biopharmaceuticals$161.92M3.95N/AN/A$3.98 per share1.59INVAInnoviva$369.84M3.25$3.70 per share5.17$10.66 per share1.79IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%6/30/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)INVAInnoviva$179.72M-$1.0127.7112.34N/A18.31%20.84%11.38%7/29/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%8/14/2025 (Estimated)Latest CDMO, DAWN, IRON, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92DAWNDay One BiopharmaceuticalsN/A14.6214.55INVAInnoviva0.381.791.64IRONDisc MedicineN/A19.3619.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%DAWNDay One Biopharmaceuticals87.95%INVAInnoviva99.12%IRONDisc Medicine83.70%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%DAWNDay One Biopharmaceuticals6.20%INVAInnoviva2.25%IRONDisc Medicine4.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableINVAInnoviva10062.78 million61.54 millionOptionableIRONDisc Medicine3034.63 million28.50 millionNot OptionableCDMO, DAWN, IRON, and INVA HeadlinesRecent News About These CompaniesDisc Medicine to Participate in Upcoming Investor ConferencesMay 28 at 4:01 PM | globenewswire.comDisc Medicine, Inc. (NASDAQ:IRON) Stock Position Raised by Deutsche Bank AGMay 28 at 3:24 AM | marketbeat.comPoint72 Asset Management L.P. Sells 742,423 Shares of Disc Medicine, Inc. (NASDAQ:IRON)May 25 at 4:04 AM | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 6,677 Shares of StockMay 23, 2025 | insidertrades.comWoodline Partners LP Boosts Stake in Disc Medicine, Inc. (NASDAQ:IRON)May 23, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Rafferty Asset Management LLCMay 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Acquires Shares of 81,190 Disc Medicine, Inc. (NASDAQ:IRON)May 19, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Northern Trust CorpMay 19, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) is MPM Bioimpact LLC's 7th Largest PositionMay 16, 2025 | marketbeat.com56,400 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Bought by Patient Square Capital LPMay 16, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New Investment in Disc Medicine, Inc. (NASDAQ:IRON)May 16, 2025 | marketbeat.comJanus Henderson Group PLC Grows Stock Position in Disc Medicine, Inc. (NASDAQ:IRON)May 15, 2025 | marketbeat.comDisc Medicine (NASDAQ:IRON) Price Target Raised to $120.00May 14, 2025 | marketbeat.comDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 CongressMay 14, 2025 | globenewswire.comDisc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceMay 14, 2025 | finance.yahoo.comDisc Medicine FY2029 EPS Forecast Lowered by HC WainwrightMay 14, 2025 | marketbeat.comFred Alger Management LLC Purchases New Position in Disc Medicine, Inc. (NASDAQ:IRON)May 13, 2025 | marketbeat.comBrevan Howard Capital Management LP Makes New $394,000 Investment in Disc Medicine, Inc. (NASDAQ:IRON)May 13, 2025 | marketbeat.comAlgert Global LLC Buys 9,397 Shares of Disc Medicine, Inc. (NASDAQ:IRON)May 13, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by The Manufacturers Life Insurance CompanyMay 13, 2025 | marketbeat.comCantor Fitzgerald Comments on Disc Medicine FY2025 EarningsMay 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDMO, DAWN, IRON, and INVA Company DescriptionsAvid Bioservices NASDAQ:CDMO$12.50 +0.02 (+0.12%) Closing price 02/5/2025Extended Trading$12.50 0.00 (0.00%) As of 02/5/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Day One Biopharmaceuticals NASDAQ:DAWN$6.31 +0.01 (+0.16%) Closing price 04:00 PM EasternExtended Trading$6.30 -0.01 (-0.10%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Innoviva NASDAQ:INVA$19.12 -0.03 (-0.16%) Closing price 04:00 PM EasternExtended Trading$19.18 +0.06 (+0.33%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Disc Medicine NASDAQ:IRON$45.12 -0.76 (-1.66%) Closing price 04:00 PM EasternExtended Trading$45.16 +0.05 (+0.10%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
